免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
完全代谢缓解作为 TIL（肿瘤浸润淋巴细胞）过继 T 细胞治疗后长期疗效的早期预测指标
英文原题：Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.
查看英文原题
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
材料与方法
纳入60例在4项不同临床试验中接受TIL治疗的患者，这些患者在基线时以及TIL输注后6-8周和/或12-16周至少有一次随访扫描时具有可用的[18F]2-氟-2-脱氧-d-葡萄糖正电子发射断层扫描-CT（FDG-PET/CT）扫描结果。
结果
获得完全代谢反应（CMR）与未获得CMR相比，与显著更优的中位总生存期（mOS）相关（p<0.0001）。特别值得关注的是，代谢反应将RECIST部分缓解者（22例患者）分为两组，其临床结局存在显著差异。部分缓解（PR）/CMR患者（10例）既未达到mOS（范围32.2-149.8+），也未达到中位无进展生存期（mPFS；范围20.7-123.4+），而PR/非CMR患者（12例）的mOS为28.7个月（p=0.0016），mPFS为7.8个月（p<0.0001）。总体而言，未达到CMR与3.2个月的较短mPFS相关，该组中97.9%（47/48）的患者在12个月内出现进展。
结论
总之，早期 CMR 是转移性黑色素瘤患者接受 TIL 治疗后长期生存的有力预测因素。此外，FDG-PET/CT 扫描在提供黑色素瘤患者 TIL 治疗后早期预后信息方面似乎优于 CT 扫描，并可用于制定患者特异性的管理和随访策略。
展开英文摘要原文
Introduction: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has proved to be an effective treatment for metastatic melanoma, even in patients failing anti-PD-1 blockade. Nevertheless, progression is observed in a substantial subgroup of patients following an initial objective response to treatment with TILs. These patients might benefit from additional consolidating treatment before clinical progression, but thus far, it is not possible to identify this subgroup of patients prone to progress. In this study the predictive value of early metabolic response after TIL therapy is explored. Materials and methods: 60 patients treated with TIL therapy in 4 different clinical trials and with available [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography-CT (FDG-PET/CT) scans at baseline and at least one follow-up scan 6-8 weeks and/or 12-16 weeks post-TIL infusion were included.
Results: Obtaining complete metabolic response (CMR) was associated with significantly superior median overall survival (mOS) compared with not obtaining CMR (p<0. 0001). Of particular interest, metabolic response divided RECIST partial responders (22 patients) into two groups with significantly different clinical outcomes.
Neither mOS (range 32. 2-149. 8+) nor median progression-free survival (mPFS; range 20. 7-123. 4+) were reached for patients with partial response (PR)/CMR (10 patients), whereas patients with PR/non-CMR (12 patients) had a mOS of 28. 7 months (p=0. 0016) and a mPFS of 7. 8 months (p<0. 0001).
Overall, not achieving a CMR was associated with a short mPFS of 3. 2 months, and 97. 9% (47/48) of all patients in this group progressed within 12 months. Conclusion: In conclusion, early CMR is a strong predictor of long-term survival after TIL therapy in metastatic melanoma patients.
Furthermore, FDG-PET/CT scans appear superior to CT scans for providing early prognostic information after TIL therapy in melanoma and can be used to tailor patient-specific management and follow-up strategies.
论文信息
- 作者
- Borch TH、Andersen R、Hendel HW、Madsen K、Ellebaek E、Marie Svane I
- 第一作者单位
- National Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark.Denmark
- 通讯作者单位
- National Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark Inge.Marie.Svane@regionh.dk.Denmark
- 期刊
- Journal for immunotherapy of cancer2025 Feb 6
- 原文标识
- PubMed 39915264 · DOI 10.1136/jitc-2024-010575
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →